Robert J. Schotzinger

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.

Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.

Arrevus, Inc. develops designer proline-rich antimicrobial peptide chaperone-protein inhibitors to treat diseases for which antibiotic resistance has clinical implications. The company was founded by Carl N. Kraus in 2015 and is headquartered in Raleigh, NC.

Propella Therapeutics, Inc. is an American biopharmaceutical company that has developed a platform combining medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Propella is based in an undisclosed location and is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care. The private company is currently in the phase 1 portion of a phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The company was founded by William E. Peterson, Charles Birbara, Milt V. Peterson, and the CEO is William Moore.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC.